KURA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KU

Mkt Cap

$807.5M

Volume

1.42M

Next Earnings

November 3rd

Loading chart

KU

KURAKura Oncology, Inc.

KURA

Pay with—

Available Balance0.00

KU

Mkt Cap

$807.8M

Volume

1.42M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

KURA Stock Gains 37.6% in a Month: Here's What You Need to KnowKura Oncology (KURA) shares gained 37.6% over the past month, driven by strong commercial momentum for its lead product Komzifti (ziftomenib), which achieved $9.1 million in Q2 2026 revenues with 57% sequential growth. The company expects multiple data readouts in 2026 and has $519 million in cash to support pipeline execution, with potential expansion of ziftomenib into earlier AML treatment lines and darlifarnib development in solid tumors.Zacks Investment Research · Sep 1, 2026

Kura Oncology to Report Second Quarter Financial ResultsKura Oncology announced it will report second quarter 2026 financial results on August 12, 2026, followed by a webcast. The company also reported durable clinical activity of its drug candidate darlifarnib plus cabozantinib in renal cell carcinoma patients, with response rates up to 50% and median PFS of 13 months observed in pre-treated, cabozantinib-naïve patients.GlobeNewswire Inc. · Aug 5, 2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLKyowa Kirin and Kura Oncology announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial for ziftomenib, an oral menin inhibitor for treating relapsed or refractory NPM1-mutated acute myeloid leukemia. Ziftomenib was previously approved by the FDA in November 2025 under the brand name KOMZIFTI. Following trial completion, Kyowa Kirin plans to file for regulatory approval in Japan.GlobeNewswire Inc. · Apr 24, 2026

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibKura Oncology announced preliminary data from the FIT-001 clinical trial showing that darlifarnib combined with cabozantinib demonstrated a 44% objective response rate and 94% disease control rate in cabozantinib-pretreated clear cell renal cell carcinoma patients. The combination showed tumor shrinkage in 75% of patients with durable treatment durations up to 56 weeks and a manageable safety profile, suggesting potential to overcome resistance to prior cabozantinib therapy.GlobeNewswire Inc. · Apr 17, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Kura Oncology granted nonstatutory stock options to purchase 153,750 shares to six new employees on April 1, 2026, with an exercise price of $8.34 per share. The options vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.GlobeNewswire Inc. · Apr 3, 2026

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsMultiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.Benzinga · Dec 4, 2025

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.GlobeNewswire Inc. · Nov 25, 2025

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) CongressKura Oncology presented preliminary clinical data at ESMO 2025 demonstrating promising results for its farnesyl transferase inhibitor (FTI) programs, showing potential in combination therapies for treating various cancer types with encouraging response rates.GlobeNewswire Inc. · Oct 18, 2025

Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug ApplicationsMarket report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.GlobeNewswire Inc. · Oct 10, 2025

10 Health Care Stocks With Whale Alerts In Today's SessionMultiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.Benzinga · Sep 29, 2025

to start trading

KU

KURAKura Oncology, Inc.

KURA

Pay with—

Available Balance0.00

Your PositionYou don't own any KURA yet.

Related Tickers

Earnings